Q-omics provides the consensus-scored GPR150 profile across patient tissues and cancer cell-line models. GPR150 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPR150 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, GPR150 RNA expression shows 12,264 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight HNSC, THCA, and PCPG as cancer lineages where GPR150 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR150 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR150 survival associations across molecular data types. GPR150 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR150 RNA expression–survival associations across cancer types. High GPR150 expression shows unfavorable associations in STAD, but favorable associations in HNSC, SCLC, LUAD, ACC and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPR150 RNA expression.
This table summarizes GPR150 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR150. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR150 shows higher tumor expression in THCA, KIRC, HNSC, KICH, KIRP and STAD. The THCA box plot shows higher GPR150 RNA expression in tumor versus normal tissue (log2 FC = +0.326, t-test p < 0.001).
This table shows molecular features associated with GPR150 in patient tissues and cancer cell lines. In patient samples, GPR150 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR150 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
